Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 7 of 87 · 4171 articles
Purinergic signaling connects nerves, immune cells, epithelium, and microbiota in the gut — pathways that can influence inflammation, motility, and pain relevant to IBD. Understanding these mechanisms could point to new...
This study aims to show how mirikizumab and other biologics perform in everyday community practice — information that can help clinicians and patients understand real-world treatment durability, symptom control, and...
Fundraisers like this support research, education, advocacy, and patient programs that can benefit people with Crohn’s disease and other forms of IBD. The story also raises awareness by centering a public figure who...
This study aims to measure how much time people with ulcerative colitis spend with objectively uncontrolled inflammation and to compare real-world outcomes of different initial advanced-therapy choices and...
A Phase 3 study is testing whether upadacitinib is safe and effective for children with moderate-to-severe Crohn's disease who have not responded to or cannot take other therapies. Positive results could expand treatment...
The study links an experimental treatment (dexpanthenol) to reduced inflammatory cytokines and improved anxiety-like behaviors in a rat colitis model, which is relevant to research on inflammation-driven gut–brain...
Noninvasive GI ultrasound (including Doppler/CEUS) could reduce the need for frequent endoscopies for monitoring IBD activity and, when combined with biomarkers, may improve accuracy of disease assessment. However,...
If reliable, blood biomarkers that track IBD activity could help noninvasively follow children with Crohn’s disease or ulcerative colitis. This study suggests MMP-9 and TIMP-1 change with disease course but did not show...
The work suggests new molecular readouts (fecal metaproteomics and lysine crotonylation) that could help explain why some people with ulcerative colitis respond to FMT while others do not, potentially guiding future...
A blood biomarker that reflects transmural inflammation could help monitor small-bowel Crohn’s disease noninvasively and might predict risk of rehospitalization.
The trial tests a naturally derived oral supplement (WPMDE2) in patients with ulcerative colitis, measuring symptoms, inflammatory markers, and quality of life—outcomes that matter to people living with IBD. Early-phase...
A registry focused on "difficult-to-treat" IBD aims to describe how often and why patients become treatment-refractory, how their disease and treatments evolve over time, and which outcomes (hospitalization, surgery,...
Cardiovascular disease is an important extraintestinal concern for people with IBD, and current risk scores may miss IBD-specific drivers. This study aims to track heart and vascular events in IBD and find biomarkers...
People with Crohn’s disease or ulcerative colitis may have higher cardiovascular risk; this prospective study aims to measure how often major heart and vascular events occur in IBD and to find biological and clinical...
First-person stories can help people with Crohn’s disease feel less alone and show ways to turn a diagnosis into advocacy or research involvement. The article highlights pediatric-to-adult transition issues and patient...
Predicting early need for infliximab could help identify children with Crohn’s disease who may benefit from earlier biologic therapy instead of prolonged conventional treatment. A reliable prediction tool may shorten...
The study identifies ABCA1 deficiency and epithelial cholesterol accumulation as drivers of colonic injury and inflammation in a hamster model, highlighting a possible new mechanism relevant to IBD pathogenesis. That...
IL-11 is implicated in fibrostenotic Crohn’s disease; determining whether it is a reversible therapeutic target could lead to treatments that prevent or reverse strictures rather than only managing inflammation or...
Patients with IBD have an increased colorectal cancer risk, and those with PSC, extensive colitis, severe inflammation, or prior dysplasia are at especially high risk. High-quality surveillance techniques can improve...
Based on the title and source metadata, this appears to be a conference abstract related to Crohn's disease, Inflammatory bowel disease, and Microbiome. The original article is from Anais do XI Congresso Médico...
Real-world data on upadacitinib help patients and clinicians understand how the drug performs outside clinical trials, including how long patients stay on treatment, remission rates, and common side effects.
The report suggests fertility treatments—particularly embryo transfer/IVF—can be successful for many women with Crohn's disease or ulcerative colitis, which may reassure patients concerned about fertility after IBD or...
Fatigue affects a large share of people with IBD and often persists despite remission; understanding treatment options and the need for a broad care plan can help patients and clinicians set realistic goals and...
The paper suggests a new animal model linking syndromic albinism mutations, intestinal inflammation, and gut-microbiome changes—areas relevant to understanding IBD biology and potential microbiome-targeted interventions.
This study identifies PLA2G2A as a drug target in experimental colitis and reports that AAIVa—an herbal-derived compound—reduced inflammation and disease measures in a mouse model, which could point to new therapeutic...
The study identifies thymoquinone as a compound that reduced inflammation and protected the intestinal barrier in a mouse colitis model, highlighting a possible new avenue for IBD drug discovery focused on the Notch...
This story highlights fundraising and awareness activities for the Crohn’s & Colitis Foundation, showing how public figures with IBD can help raise funds and visibility for the community.
The study provides first human evidence that a single colonoscopic FMT can eradicate mucosal adherent-invasive E. coli (AIEC), a bacterium linked to Crohn’s disease, and it shows associated shifts in mucosal microbiota...
Fundraising events support research, education, advocacy, and direct patient services that can benefit people living with Crohn’s disease and other forms of IBD. A public figure with lived experience being honored can...
This preclinical work suggests the gut microbiota and tryptophan-derived metabolites that activate AhR may be important in reducing colitis-related inflammation — a potential route for future therapies relevant to...
Support organizations can offer education, peer connection, mental-health services, advocacy, and programs for children and families that complement medical care. Knowing where to find these resources can help people...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Ct Enterography. The original article is from idp.springer.com.
Deep remission is an emerging treatment target in Crohn’s disease that combines symptoms and objective measures. A meaningful proportion of patients in VIVID-1 achieved corticosteroid-free deep remission with mirikizumab...
An oral IL-23 blocker showed benefit in a Phase IIb trial for moderate-to-severe ulcerative colitis, which could add a new pill option for patients—especially those who’ve failed injectable biologics.
Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Diet and lifestyle. Open the original article for the full details.
Cure8 found this source from fiercepharma.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Mirikizumab, and IL-23 inhibitor. Open the original article for the full details.
The study suggests a dietary protein (ovotransferrin) can reduce colitis severity in mice by changing the gut microbiota and increasing certain secondary bile acids that lower inflammation and gut permeability.
These results suggest mirikizumab can achieve multiple treatment goals at once — symptoms, objective inflammation measures, and steroid-free status — outcomes that matter to people with IBD because they reflect both...
This study connects USP25 to NOD2–XIAP signaling and Crohn’s disease genetics, suggesting a possible target for future therapies or biomarkers relevant to IBD pathogenesis.
Capsaicin is commonly consumed and acts on TRPV1, which is increased in inflamed IBD tissue; depending on dose and disease activity it may help or worsen inflammation and symptom-related pain.
MMP-2 regulates tissue remodeling and inflammation in IBD; targeting it might help prevent barrier damage, chronic inflammation, or fibrosis but requires selective approaches to avoid harming normal repair processes.
The paper suggests a specific gut bacterium and its metabolite can protect against intestinal inflammation in mice by acting on enteric neurons, revealing a new neuro-immune pathway that could inform future IBD...
A phase 2 trial testing an oral integrin α4β7 inhibitor could matter because it explores a potential new mechanism for treating moderately to severely active ulcerative colitis, including patients who have failed other...
Findings highlight cultivable gut microbiota differences in Crohn’s disease versus controls and present preliminary in vitro antimicrobial activity of two thyme essential oils—topics that may interest patients following...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Mental health and quality of life. The original article is from BMC Gastroenterology.
Microbiota-derived metabolites are linked to inflammation and gut barrier function, so they could become biomarkers or therapeutic targets for Crohn’s disease and ulcerative colitis. Patients may see future tests or...
This research links a gut bacterial metabolite to modulation of an immune receptor (GPR183) that is elevated in colon/rectum of ulcerative colitis patients, suggesting a possible microbiota‑to‑immune pathway relevant to...
Findings suggest GM-CSF signaling may help limit epithelial injury and shape immune cell states in Crohn’s disease, which could be relevant to understanding inflammation and future therapies targeting innate immunity or...
